Market Overview

UPDATE: Bank of America Reiterates on Karyopharm Therapeutics on Significant Catalysts in 2014


In a report published Thursday, Bank of America analyst Steve Byrne reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), and raised the price target from $40.00 to $48.00.

In the report, Bank of America noted, “We are raising our PO to $48 (from $40) based on the potential for use in solid tumors beyond our previously modeled colorectal cancer estimates. We maintain our 25% probability of approval estimate, which could increase post updates at ASCO and EHA (below). Two registration studies in elderly AML and DLBCL are expected to start this year, based on compelling phase 1 data. KPTI also plans to start several phase 2 trials in solid tumors in 2014.

"We maintain our Buy rating and view Selinexor as having significant anti-tumor efficacy and potential as part of a larger oncology platform due to its broad scope and likely synergies with other cancer therapies. We expect significant news flow for Selinexor in 2014 in both solid and hematologic malignancies, which could add upside to our estimates.”

Karyopharm Therapeutics closed on Wednesday at $37.99.

Latest Ratings for KPTI

Nov 2020Morgan StanleyMaintainsOverweight
Nov 2020SVB LeerinkMaintainsOutperform
Aug 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for KPTI
View the Latest Analyst Ratings


Related Articles (KPTI)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Price Target Analyst Ratings

Latest Ratings

ZMRBC CapitalMaintains550.0
ZMJP MorganMaintains450.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at